Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
Jiangsu Hengrui Medicine Co., Ltd.
No. 38, Huanghe Road
Economic and Technological Development Zone
Lianyungang 222000
China
https://www.hrs.com.cn
Sector(es): Healthcare
Industria: Drug Manufacturers - General
Empleados a tiempo completo: 19,611
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Hong Bin Dai | GM & Director | N/D | N/D | 1976 |
| Mr. Jianjun Liu | Financial Director | N/D | N/D | 1978 |
| Mr. Jie Ping Sun | Deputy GM & Director | N/D | N/D | 1970 |
| Dr. Lian Shan Zhang Ph.D. | Deputy GM & Director | N/D | N/D | 1962 |
| Dr. Ningjun Jiang M.D., Ph.D. | Deputy GM & Director | N/D | N/D | 1961 |
| Ms. Xiao Han Liu | Secretary of the Board of Directors | N/D | N/D | 1985 |
| Ms. Su Mei Jiang | Deputy General Manager | N/D | N/D | 1965 |
| Mr. Ya Ping Shen | Deputy General Manager | N/D | N/D | 1964 |
| Mr. Cheng Liao | Deputy General Manager | N/D | N/D | 1975 |
| Mr. Hongsen Wang | Deputy General Manager | N/D | N/D | 1970 |
Descripción
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.
Gestión corporativa
La calificación ISS Governance QuickScore de Jiangsu Hengrui Medicine Co., Ltd. a partir del 1 de junio de 2024 es 2. Las puntuaciones principales son Auditoría: 5; Junta: 7; Derechos del accionista: 2; Compensación: 1.
